Skip to main content

Interferon beta behandlingar, så som Plegridy® (peginterferon beta-1a) och Avonex® (interferon beta-1a), fick positivt CHMP utlåtande för användning under graviditet och amning

Pressmeddelande   •   Sep 24, 2019 13:34 CEST

  • Det positiva utlåtandet grundas på data från över 1000 graviditeter
  • Data indikerar inte någon ökad risk för allvarliga medfödda defekter efter interferon beta exponering före befruktning och/eller under första trimestern.
  • Data visar att utfallen från graviditeterna ligger i linje med utfallen för graviditeter i den allmänna befolkningen

Cambridge, Mass. September 23, 2019 Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP), part of the of the European Medicines Agency (EMA), recommended an update to marketing authorizations of approved interferon beta treatments, including Plegridy® (peginterferon beta-1a) and Avonex® (interferon beta-1a), to remove pregnancy contraindications and, where clinically needed, to allow use during pregnancy and breastfeeding in women with relapsing multiple sclerosis (MS).

“Women are diagnosed with MS at least two to three times more frequently than men,[1] and the disease may strike during their child-bearing years.[2] Choosing a treatment plan that allows women to continue or start their MS therapy while pregnant or breastfeeding is a step forward for those living with this chronic, debilitating disease and their partners,” said Alfred Sandrock, Jr., M.D., Ph.D., executive vice president and chief medical officer at Biogen. “This CHMP opinion gives physicians and their patients added confidence when considering treatment with Plegridy or Avonex, two therapy options for relapsing MS that have been prescribed to more than half a million people living with the disease.”

The CHMP opinion is based on data from the European Interferon Beta Pregnancy Registry, as well as the national health registers in Finland and Sweden, which together created the largest cohort studies providing safety data related to interferon beta exposure in women of child-bearing age with MS.

Data collected from more than 1,000 pregnancy outcomes from registries and post-marketing experience indicate no increased risk of major congenital anomalies following exposure to interferon beta before conception or during the first trimester of pregnancy. However, the duration of exposure during the first trimester is uncertain, because data were collected when interferon beta use was contraindicated during pregnancy, and treatment was likely interrupted when the pregnancy was detected and/or confirmed. Additionally, experience with exposure in the second and third trimesters is very limited. The risk of spontaneous abortions in pregnant women exposed to interferon beta cannot adequately be evaluated based on the currently available data, but the data do not suggest an increased risk so far.Limited data suggest the levels of interferon beta-1a excreted in human milk are negligible, and no harmful effects on the breastfed newborn/infant are anticipated.

Om Plegridy

Plegridy är avsett för vuxna patienter för behandling av skovvis förlöpande multipel skleros, vilket är den vanligaste formen av multipel skleros. De vanligaste biverkningarna, i kliniska studier, var erytem vid injektionsstället och influensaliknande symtom. Fertila kvinnor ska använda effektiv preventivmetod. För ytterligare information om förpackningar, kontraindikationer, varningar och försiktighet, biverkningar och pris, se

Om Avonex

Avonex är avsett för vuxna patienter för behandling av skovvis förlöpande multipel skleros, vilket är den vanligaste formen av multipel skleros. Den vanligaste biverkningen, i kliniska studier var influensaliknande symtom. Kvinnor i fertil ålder skall använda lämpliga preventivmetoder. För ytterligare information om förpackningar, kontraindikationer, varningar och försiktighet, biverkningar och pris, se

About BiogenAt Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, neuromuscular disorders, movement disorders, Alzheimer’s disease and dementia, ophthalmology, immunology, neurocognitive disorders, acute neurology and pain.

Biogen Safe Harbor

This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about the potential benefits, safety and efficacy of PLEGRIDY and AVONEX; the results of certain real-world data; our research and development program for the treatment of MS; plans for additional regulatory filings in other jurisdictions; and risks and uncertainties associated with drug development and commercialization. These statements may be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “except,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation the occurrence of adverse safety eventsand/or unexpected concerns that may arise from additional data or analysis; failure to obtain regulatory approvals in other jurisdictions; regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of expansion of product labeling; risks of unexpected costs or delays; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; and product liability claims. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this news release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

[1] Multiple Sclerosis Coalition. The Use of Disease-modifying Therapies in Multiple Sclerosis Principles and Current Evidence. Updated March 2017.

[2] Coyle PK. Pregnancy and multiple sclerosis. Neurol Clin. 2012 Aug;30(3):877-88. doi: 10.1016/j.ncl.2012.05.002. Epub 2012 Jun 22.


Mats Ekelund

+46 76 182 36 27

Om Biogen
Biogen är ett av världens ledande bioteknikföretag och gör stora satsningar i Sverige och övriga Norden. Biogens fokus ligger på att utveckla läkemedel mot svåra sjukdomar där det i dag finns få eller inga behandlingsmöjligheter. Bolaget har en omfattande forskning inom neurologi och immunologi samt är ledande inom MS i Sverige och i världen.